Skip to content

Genetics of Arteriovenous Malformations

Genetics of Arteriovenous Malformations

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02445430
Enrollment
59
Registered
2015-05-15
Start date
2015-05-31
Completion date
2023-06-30
Last updated
2021-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arteriovenous Malformation

Brief summary

The goal of this study is to identify genetic alterations resulting in the development of arteriovenous malformation (AVM) in the central nervous system.

Detailed description

The study will include AVM patients and members of their nuclear family. All patients will donate a sample of saliva (5 mL) or blood (10 mL). Basic demographic and clinical parameters will be collected, including ethnicity, age at first presentation, symptoms at presentation, history of subsequent symptoms, treatment history, Spetzler-Martin AVM grade, medication history, and other pertinent medical information. In patients undergoing AVM resection, a small sample of the AVM will be collected for concurrent genomic analysis. Family members will donate saliva (5mL) and document their relationship to the patient (i.e., parent, sibling, child, etcl). Nucleic acids will be isolated from the saliva/blood samples, and genetic sequencing will be carried out. When a surgical sample of the AVM is available, nucleic acids will be obtained and transcriptome profiling will be performed. Identification of genetic alterations common to patients with AVM and not present in samples from parents and siblings will greatly aid in identification of pathways associated with AVM formation. Candidate sequences will be chosen by differential expression (p\<0.05) and fold-changes. Once identified, mechanisms for the rapid detection of marker sequences will be developed and their predictive value tested in future collections.

Interventions

None listed

Sponsors

Translational Genomics Research Institute
CollaboratorOTHER
The Joe Niekro Foundation
CollaboratorUNKNOWN
St. Joseph's Hospital and Medical Center, Phoenix
Lead SponsorOTHER

Study design

Observational model
FAMILY_BASED
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
6 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Age between 6 and 60 years inclusive * Diagnosis of AVM or nuclear family member of a patient with AVM * Grants access to saliva, blood, and/or tissue

Exclusion criteria

* Age less than 6 years or greater than 61 years * Nuclear family members who do not share the same parents as the AVM patient

Design outcomes

Primary

MeasureTime frame
Identification of genetic alterations common to patients with AVMsample analysis will take an expected average of six weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026